Introdução: A modulação da resposta imune em muitas situações clínicas persiste como um dos problemas mais desafiadores em imunologia. Citocinas são fundamentais para esta regulação e são amplamente estudadas. Após a ligação com receptores específicos na superfície das células alvo, uma das principais vias de sinalização é o sistema JAKs/STATs. No entanto, em contraste com as citocinas, não existem estudos detalhados sobre a cinética expressão intracelulares de STAT in vitro. Objetivo: Determinar por citometria de fluxo, a cinética expressão de proteínas STAT 1, 3, 4, 5 e 6 fosforiladas, a produção de citocinas associadas e expressão de seus receptores em PBMC humanas estimuladas in vitro com fito-hemaglutinina (PHA) e antígeno de citomegalovírus (CMV). Metodologia: Foram avaliados CMNs de 23 doadores saudáveis em relação à cinética de expressão STATs (12 doadores estimulados com PHA e 11 estimulados com CMV), secreção de citocinas e expressão de seus receptores. Resultados: Em células estimulada com PHA e CMV, pSTAT1 e 6 tiveram sua expressão aumentada precocemente (4h e três dias, respectivamente). pSTAT3 teve sua expressão aumentada em momentos posteriores (respectivamente 36h e 6 dias). A indução de expressão de pSTAT4 e 5 foi observada nos tempos mais tardios da cinética em células estimuladas com PHA (24-36h), enquanto observamos constante baixo nível de expressão em todos os tempos analisados em células estimuladas com CMV. No que diz respeito á secreção de citocinas em células estimuladas com PHA, níveis maiores de IL-6, IL-10 e IL-4 foram detectados a partir de 12h, enquanto aumento da secreção de IFN-y e IL-2 ocorreu a partir de 24h. Com CMV, apenas IL-6 mostrou um aumento da secreção nos dias 4 e 6. Os receptores de citocinas CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL -2) e CD124 (IL-4) tiveram um aumento da expressão após 24-36h de estimulação com PHA. Com estímulo de CMV, CD126, CD212, CD25, também aumentaram a expressão em tempos tardios (5-6 dias), enquanto os outros receptores mantiveram níveis baixos de expressão em todos os momentos estudados. Discussão: Houve uma correlação entre a cinética de expressão de pSTAT3 e 5, e a cinética das citocinas associadas e de seus receptores (IL-6 / CD126, IL-10 / CD210 e IL-2 / CD25). A cinética de expressão de pSTAT4 se correlacionou com a expressão de CD212. (IL-12p70 não foi detectada no presente estudo). Entretanto a expressão de pSTAT1 e 6 precedeu à de IFN-y / CD119 e IL-4 / CD124. Conclusão: A determinação da cinética de expressão pSTAT in vitro pode contribuir para a compreensão da regulação da resposta imune a patógenos distintos e, potencialmente, ajudar no desenvolvimento de novos alvos terapêuticos bem como de novas estratégias destinadas a modular as vias de sinalização em diversas condições clínicas associadas à desregulação imunológica / Introduction: Modulation of immune responses in many clinical situations persists as one of the most challenging issues in immunology. Cytokines are fundamental to this regulation and have already been extensively studied. After binding with its specific receptors on the surface of the target cells, the main signaling pathway is the JAKs/STATs system. However, in contrast to cytokines, there are no detailed studies on the in vitro intracellular expression kinetics of STATs. Objective: To determine by flow cytometry the kinetics of phosphorylated STAT1, 3, 4, 5 and 6 proteins expression in human PBMCs in vitro stimulated with phytohemagglutinin (PHA) and cytomegalovirus antigen (CMV), and the associated cytokine production and cytokine receptors expression. Methodology: We evaluated PBMCs from 23 healthy donors regarding the kinetics of STATs expression (12 donors stimulated with PHA and 11 stimulated with CMV), cytokine secretion and respective receptors expression. Results: In PHA and CMV stimulated cells, pSTAT 1 and 6 expression increased early, 4h and 3days respectively). pSTAT3 expression augmented at later times (respectively 36h and 6 days). pSTAT4 and 5 expression were observed late in PHA stimulated cells (24-36h), while there was a constantly low level of expression in all times analyzed. Regarding cytokine release In PHA stimulated cells, IL-6, IL10 and IL-4 secretion started to increase at 12h while IFN-y and IL-2 increased at 24h. With CMV, only IL-6 showed increased expression at days 4 and 6. The cytokines receptors CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL-2) and CD124 (IL-4) had increased expression at 24-36h with PHA stimulation. With CMV stimulation, CD126, CD212, CD25 also had increased expression at late times (5-6 days) while the other receptors maintained low expression levels at all times. Discussion: There was a correlation in between the pSTAT3 and 5 expression kinetics and the associated cytokines and cytokine receptors kinetics (IL-6/CD126, IL-10/CD210 and IL-2/CD25. pSTAT4 expression kinetics correlated with that of CD212 expression (IL-12p70 was not detected in the present study). The higher pSTAT1 and 6 expressions preceded that of IFN-y/CD119 and IL-4/CD124, respectively. Conclusion: Determination of pSTAT expression kinetics in vitro can contribute to the understanding of the regulation of immune responses to distinct pathogens and potentially help in the design of new therapeutic targets as well as new strategies aimed at modulating signaling pathways

Introdução: A modulação da resposta imune em muitas situações clínicas persiste como um dos problemas mais desafiadores em imunologia. Citocinas são fundamentais para esta regulação e são amplamente estudadas. Após a ligação com receptores específicos na superfície das células alvo, uma das principais vias de sinalização é o sistema JAKs/STATs. No entanto, em contraste com as citocinas, não existem estudos detalhados sobre a cinética expressão intracelulares de STAT in vitro. Objetivo: Determinar por citometria de fluxo, a cinética expressão de proteínas STAT 1, 3, 4, 5 e 6 fosforiladas, a produção de citocinas associadas e expressão de seus receptores em PBMC humanas estimuladas in vitro com fito-hemaglutinina (PHA) e antígeno de citomegalovírus (CMV). Metodologia: Foram avaliados CMNs de 23 doadores saudáveis em relação à cinética de expressão STATs (12 doadores estimulados com PHA e 11 estimulados com CMV), secreção de citocinas e expressão de seus receptores. Resultados: Em células estimulada com PHA e CMV, pSTAT1 e 6 tiveram sua expressão aumentada precocemente (4h e três dias, respectivamente). pSTAT3 teve sua expressão aumentada em momentos posteriores (respectivamente 36h e 6 dias). A indução de expressão de pSTAT4 e 5 foi observada nos tempos mais tardios da cinética em células estimuladas com PHA (24-36h), enquanto observamos constante baixo nível de expressão em todos os tempos analisados em células estimuladas com CMV. No que diz respeito á secreção de citocinas em células estimuladas com PHA, níveis maiores de IL-6, IL-10 e IL-4 foram detectados a partir de 12h, enquanto aumento da secreção de IFN-y e IL-2 ocorreu a partir de 24h. Com CMV, apenas IL-6 mostrou um aumento da secreção nos dias 4 e 6. Os receptores de citocinas CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL -2) e CD124 (IL-4) tiveram um aumento da expressão após 24-36h de estimulação com PHA. Com estímulo de CMV, CD126, CD212, CD25, também aumentaram a expressão em tempos tardios (5-6 dias), enquanto os outros receptores mantiveram níveis baixos de expressão em todos os momentos estudados. Discussão: Houve uma correlação entre a cinética de expressão de pSTAT3 e 5, e a cinética das citocinas associadas e de seus receptores (IL-6 / CD126, IL-10 / CD210 e IL-2 / CD25). A cinética de expressão de pSTAT4 se correlacionou com a expressão de CD212. (IL-12p70 não foi detectada no presente estudo). Entretanto a expressão de pSTAT1 e 6 precedeu à de IFN-y / CD119 e IL-4 / CD124. Conclusão: A determinação da cinética de expressão pSTAT in vitro pode contribuir para a compreensão da regulação da resposta imune a patógenos distintos e, potencialmente, ajudar no desenvolvimento de novos alvos terapêuticos bem como de novas estratégias destinadas a modular as vias de sinalização em diversas condições clínicas associadas à desregulação imunológica / Introduction: Modulation of immune responses in many clinical situations persists as one of the most challenging issues in immunology. Cytokines are fundamental to this regulation and have already been extensively studied. After binding with its specific receptors on the surface of the target cells, the main signaling pathway is the JAKs/STATs system. However, in contrast to cytokines, there are no detailed studies on the in vitro intracellular expression kinetics of STATs. Objective: To determine by flow cytometry the kinetics of phosphorylated STAT1, 3, 4, 5 and 6 proteins expression in human PBMCs in vitro stimulated with phytohemagglutinin (PHA) and cytomegalovirus antigen (CMV), and the associated cytokine production and cytokine receptors expression. Methodology: We evaluated PBMCs from 23 healthy donors regarding the kinetics of STATs expression (12 donors stimulated with PHA and 11 stimulated with CMV), cytokine secretion and respective receptors expression. Results: In PHA and CMV stimulated cells, pSTAT 1 and 6 expression increased early, 4h and 3days respectively). pSTAT3 expression augmented at later times (respectively 36h and 6 days). pSTAT4 and 5 expression were observed late in PHA stimulated cells (24-36h), while there was a constantly low level of expression in all times analyzed. Regarding cytokine release In PHA stimulated cells, IL-6, IL10 and IL-4 secretion started to increase at 12h while IFN-y and IL-2 increased at 24h. With CMV, only IL-6 showed increased expression at days 4 and 6. The cytokines receptors CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL-2) and CD124 (IL-4) had increased expression at 24-36h with PHA stimulation. With CMV stimulation, CD126, CD212, CD25 also had increased expression at late times (5-6 days) while the other receptors maintained low expression levels at all times. Discussion: There was a correlation in between the pSTAT3 and 5 expression kinetics and the associated cytokines and cytokine receptors kinetics (IL-6/CD126, IL-10/CD210 and IL-2/CD25. pSTAT4 expression kinetics correlated with that of CD212 expression (IL-12p70 was not detected in the present study). The higher pSTAT1 and 6 expressions preceded that of IFN-y/CD119 and IL-4/CD124, respectively. Conclusion: Determination of pSTAT expression kinetics in vitro can contribute to the understanding of the regulation of immune responses to distinct pathogens and potentially help in the design of new therapeutic targets as well as new strategies aimed at modulating signaling pathways

The cytokines GM-CSF, IL-3 and IL-5 are central regulators of haemopoietic cell functions and are pivotal in the regulation of haemopoiesis and inflammatory responses of myeloid cells. In particular, these cytokines have been shown to perform essential functions in host defence against foreign pathogens through their ability to regulate innate immune responses in myeloid cells. As key regulators of such important processes, these cytokines play an important role in human inflammatory pathologies such as rheumatoid arthritis, asthma, multiple sclerosis and psoriasis as well as a number of leukemias such as JML and CMML. GM-CSF, IL-3 and IL-5 signal through receptors containing α subunits specific to each cytokine and a common β subunit (βc). Cytokine stimulation leads to tyrosine phosphorylation of the βc and promotes specific responses such as proliferation, survival and activation of haemopoietic cells. Mouse knockout studies identified a key function of these cytokines in the activation of effector functions of myeloid cells, including production of reactive oxygen species (ROS) and phagocytosis. These earlier studies provide a link between cytokine signalling and inflammation, but the molecular mechanisms by which βc activation regulates effector cell functions, and the receptor motifs involved, are unknown. The aim of this thesis was to address two broad questions with regard to βc signalling: (1) Does βc regulate specific cellular responses by phosphotyrosine-independent mechanisms? (2) What are the molecular mechanisms by which βc initiates signalling to promote specific biological responses such as activation of effector cell functions? To address the first question, we have focussed on Serine 585, a potential 14-3-3 binding site which lies in the cytoplasmic potion of huβc. Out results show that the mutation huβc S585G disrupted the interaction of 14-3-3ζ with βc, whilst not affecting receptor tyrosine phosphorylation. Both mouse and human βc were shown to interact with 14-3-3 proteins, indicating that this interaction is conserved between these species. Significantly, a huβc S585G mutant was unable to promote haemopoietic cell survival in response to IL-3. These results identify a new mechanism by which cytokine receptors are able to couple to downstream signalling pathways that regulate cell survival. An approach was developed and optimised to analyse specific GM-CSF-mediated responses in monocytes/macrophages expressing wildtype or mutant huβc, (including huβc S585G that was defective in regulating survival). Bone marrow-derived muβc -/-;muβIL-3 -/- monocytes/macrophages were retrovirally transduced with constructs expressing wildtype or mutant huβc, along with huGMRα, then purified by FACS. Two assays were established to measure effector functions in the transduced monocyte/macrophages; (1) a flow cytometry assay for ROS production, and (2) an assay for phagocytosis. The capacity for GM-CSF to prime (i.e. enhance effector functions) ROS production and phagocytosis was investigated in huGMRα-transduced monocytes/macrophages. Our results have identified two key residues in the cytoplasmic domain of βc subunit: Tyrosine 577 (required for huβc interaction with the adaptor protein Shc) and serine 585 (required for 14-3-3 association), that are essential for the ability of GM-CSF to regulate key effector functions in monocytes/macrophages. These novel findings are significant in that they establish a molecular link between the GM-CSF/IL-3/IL-5 receptor and the regulation of both haemopoietic cell survival and inflammatory responses, and therefore have important implications in our understanding of inflammatory diseases such as rheumatoid arthritis and asthma. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1317007 / Thesis (Ph.D.) -- University of Adelaide, School of Medicine, 2008

Lymphomas are neoplasms of the human immune system and can be divided into two categories, Hodgkin’s lymphoma (HL) and non-Hodgkin lymphoma (NHL). Anaplastic large cell lymphoma (ALCL) is a form of NHL that shares a common distinctive feature with HL, the overexpression CD30. The expression of cytokine receptor CD30 is restricted to proliferating B and T lymphocytes in healthy individuals while its overexpression is associated with several lymphoproliferative diseases such as ALCL and HL. The activation of CD30 via ligand or antibodies triggers various cellular responses ranging from apoptosis to cell proliferation and it is thought that the variable cellular response to CD30 activation may be due to cell surface levels of CD30. The human CD30 gene is regulated at the transcriptional level and previous studies characterising its promoter have identified several factors that regulate the expression this gene. However none of these identified factors explain for the high levels of CD30 observed in HL and ALCL. Therefore this study focused on the identification and functional analysis of transcriptionally active regions located up or downstream of the CD30 promoter region. The first aim for this study was to identify and characterise regions within the human CD30 gene that are involved in its transcriptional regulation. Phylogenetic footprinting identified several regions downstream of the CD30 promoter that displayed high levels of sequence homology indicating potential functional significance. Validation of these regions through two in vivo approaches, DNase 1 hypersensitivity assay and chromatin accessibility studies localised potential transcriptionally active regions to intron 1 of the CD30 gene.